RT Journal Article
SR Electronic
T1 Role of favipiravir in the treatment of adult patients with moderate to severe COVID-19: a single-center, prospective, observational, sequential cohort study from Hungary
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.11.26.20238014
DO 10.1101/2020.11.26.20238014
A1 Szabo, Balint Gergely
A1 Lenart, Katalin Szidonia
A1 Petrik, Borisz
A1 Gaspar, Zsofia
A1 Balogh, Zsofia
A1 Banyai, Zsuzsanna
A1 Banyasz, Emese
A1 Budai, Jozsef
A1 Czel, Eszter
A1 Fried, Katalin
A1 Hanuska, Adrienn
A1 Kiss-Dala, Noemi
A1 Lorinczi, Csaba
A1 Nemesi, Krisztina
A1 Kadar, Janos
A1 Nagy, Eva Livia
A1 Osvald, Akos
A1 Petrovicz, Edina
A1 Riczu, Alexandra
A1 Szanka, Judit
A1 Szathmary, Beata
A1 Szombati, Andrea
A1 Toth, Szilvia
A1 Varnai, Zsuzsanna
A1 Woller, Orsolya
A1 Szlavik, Janos
A1 Lakatos, Botond
YR 2020
UL http://medrxiv.org/content/early/2020/12/09/2020.11.26.20238014.abstract
AB Background Preliminary data suggests that favipiravir might have a role in COVID-19 treatment. Our aim was to assess the role of favipiravir in the treatment of COVID-19.Methods A single-center, prospective, observational, sequential cohort study was performed among consecutive adults hospitalized with PCR-confirmed COVID-19 between March– July,2020. Patients were screened for inclusion by a priori criteria, and were included in the favipiravir cohort if SOC+FVP, or the non-favipiravir group if SOC±other antiviral medications without FVP were administered for >48 hours. Treatment allocation was done per national guidelines. For COVID-19 diagnosis and severity, ECDC and WHO definitions were utilized, and daily per protocol hospital follow-up was done. Primary composite end-point was disease progression (14-day all-cause death, need for mechanical ventilation, or immunomodulatory therapy). For statistical comparison, Fisher’s exact test and Mann– Whitney U-test were used.Results In all, 75 patients were included per cohort. In the FVP cohort, chronic heart disease (36/75, 48.0% vs. 16/75, 21.3%, p<0.01) and diabetes mellitus (23/75, 30.7% vs. 10/75, 13.3%, p<0.01) were more prevalent, hospital LOS (18.5±15.5 days vs. 13.0±8.5 days, p<0.01) was higher. Disease progression (17/75, 22.7% vs. 10/75, 13.3%, p=0.13), 14-day all-cause death (9/75, 12.0% vs. 10/75, 13.3%, p=0.8) and need for mechanical ventillation (8/75, 10.7% vs. 4/75, 5.3%, p=0.22) were similar between groups. Immunomodulatory therapies were administered frequently among patients receiving FVP (10/75, 13.3% vs. 1/75, 1.3%, p<0.01).Conclusions In this study, favipiravir did not seem to affect disease progression. Further data are needed to position this drug among the anti-SARS-CoV-2 armamentarium.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe article itself did not receive any external funding. BGSz received the EFOP-3.6.3-VEKOP-16-2017-00009 Doctorate Grant, and was supported by the UNKP-19-3-I-SE-74 New National Excellence Program of the Ministry of Innovation and Technology of Hungary. The funding sources had no involvement in the preparation, writing, interpretation, or submission of this article.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Institutional Review Board of South Pest Central Hospital, National Institute of Hematology and Infectious Diseases (Budapest, Hungary) approved the study protocol. Approval for the use of off-label investigational drugs was granted by our institutional review board, as well as the National Institute of Pharmacy and Nutrition in relation to the COVID-19 surge in Hungary (ogyei.gov.hu/tajekoztato_a_veszelyhelyzet_megszunesevel_kapcsolatos_a_covid_19_jarvany_idejen_kulonos_meltanylast_erdemlo_betegellatasi_erdekhez_kotheto_gyogyszeralkalmazasok_bejelenteserol).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAnonymised data of patients are available from the corresponding author on reasonable request.ARDSacute respiratory distress syndromeBALbronchoalveolar lavageCOVID-19coronavirus disease-19CRPC-reactive proteinCScytokine stormCTcomputed tomographyECDCEuropean Centre for Disease Prevention and ControlEUCASTEuropean Committee on Antimicrobial Susceptibility TestingFVPfavipiravirICUintensive care unitIQRinterquartile regionLDHlactate dehydrogenaseLOSlength of stayPCRpolymerase chain reactionRCTrandomized clinical trialsSARS-CoV-2severe acute respiratory syndrome coronavirus-2SOCstandard of careSTROBEStrengthening the Reporting of Observational studies in Epidemiology